MEDCOM USA INC
NT 10-K, 2000-09-28
TELEPHONE COMMUNICATIONS (NO RADIOTELEPHONE)
Previous: DRUMMOND FINANCIAL CORP, 10-K405, EX-27, 2000-09-28
Next: FX ENERGY INC, 424B3, 2000-09-28





                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                                       SEC File Number 0-25474
                                                       CUSIP Number 584 06 2103

                                   FORM 12b-25

                           NOTIFICATION OF LATE FILING

                                  (Check One):

[X] Form 10-K  [  ] Form 20-F  [  ] Form 11-K  [  ] Form 10-Q  [  ] Form N-SAR

For Period Ended: June 30, 2000
---------------------------------

    Nothing in this Form shall be  construed  to imply that the  Commission  has
verified any information contained herein.

---------------------------------

     If the  notification  relates  to a portion of the  filing  checked  above,
identify the Item(s) to which the notification relates: N/A

---------------------------------

Part I - Registrant Information

---------------------------------

Full Name of Registrant:  Medcom USA, Incorporated

Former Name if Applicable:  Sims Communications, Inc.

Address of Principal Executive Office (Street and Number)

    18001 Cowan, Suites C&D

City, State and Zip Code

    Irvine, California 92614
---------------------------------

Part II - Rules 12b-25(b) and (c)
---------------------------------

<PAGE>

    If the subject  report  could not be filed  without  unreasonable  effort or
expense  and  the  registrant  seeks  relief  pursuant  to Rule  12b-25(b),  the
following should be completed. (Check box if appropriate)

    (a)  The reasons  described  in  reasonable  detail in Part III of this form
         could not be eliminated without unreasonable effort or expense;

[X] (b)  The subject annual report, semi-annual report, or transition report
         or portion  thereof will be filed on or before the  fifteenth  calendar
         day following the prescribed due date; or the subject  quarterly report
         or transition  report on Form l0-Q or portion  thereof will be filed on
         or before the fifth calendar day following the prescribed due date; and

    (c)  The accountant's  statement or other exhibit required by Rule 12b-25(c)
         has been attached if applicable.
------------------------------------

Part III - Narrative
------------------------------------

    State below in reasonable  detail the reasons why the Form 10-K, 20-F, 11-K,
10-Q, or N-SAR,  or the transition  report or portion thereof could not be filed
within the prescribed time period.

    The  Company is  rewriting  certain  sections of the 10-K report so that the
description of the Company's business reflects the Company's  continued focus on
providing products and services to the healthcare  industry.  As a result,  more
time is needed to complete the report.
-------------------------------------

Part IV - Other Information
-------------------------------------

(1)  Name  and  telephone  number  of  person  to  contact  in  regard  to  this
     notification

               William T. Hart             (303)              839-0061
              -----------------            -----              --------
                   (Name)               (Area Code)      (Telephone Number)



<PAGE>


    (2)  Have all other periodic  reports  required under Section 13 or 15(d) of
         the Securities  Exchange Act of 1934 during the preceding l2 months (or
         for such shorter  period that the  registrant was required to file such
         reports) been filed? If answer
         is no, identify report(s).                       [X] Yes  [  ] No

    (3)  Is it anticipated that any significant  change in results of operations
         from  the  corresponding  period  for  the  last  fiscal  year  will be
         reflected by the earnings statements to be included
         in the subject report or portion thereof?        [  ] Yes  [X] No

         If  so:  attach  an  explanation  of  the  anticipated   change,   both
         narratively and quantitatively,  and, if appropriate, state the reasons
         why a reasonable estimate of the results cannot be made.

                            Medcom USA, Incorporated
                  (Name of Registrant as specified in charter)

has  caused  this  notification  to be signed on its  behalf by the  undersigned
thereunto duly authorized.


Date:  September 28, 2000          By    /s/ Alan Ruben
                                         -----------------------------------
                                         Alan Ruben, Principal Financial Officer
                                         Medcom USA, Incorporated
                                         18001 Cowan, Suite C & D
                                         Irvine, CA 92614
                                         (949) 261-6665

                                    ATTENTION

     Intentional  misstatements or omissions of fact constitute Federal Criminal
Violations (See 18 U.S.C. 1001).





© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission